Name (Synonyms) | Correlation | |
---|---|---|
drug2069 | Patient sampling Wiki | 1.00 |
drug1869 | Nitazoxanide Wiki | 0.32 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The efficacy of treating COVID-19 infection by using Sofosbuvir/Ledipasvir and Nitazoxanide will be examined. Included patients will be into 3 groups. The 1st group will receive Sofosbuvir/Ledipasvir plus the standard care treatment (SCT). The 2nd group will take Nitazoxanide and SCT, while the 3rd group will receive only SCT. Then the clinical improvement and the rate of PCR change from positive to negative will be evaluated in each group.
Description: The PCR will be done at time of recruitment, day 5, 8, 11, and 14. The time taken to have negative will be measured in each group.
Measure: Change of PCR from positive to negative Time: 2 weeksDescription: Clinical improvement will be measured by detection of downgrading of cases severity according to the World Health Organization case severity classification.
Measure: Clinical improvement Time: 2 weeksDescription: All patients will be asked about any possible adverse effects that they may suffer from taken drugs during their follow up. Any mentioned side effect will be reported. Drug discontinuation and it cause will be also reported if it happened.
Measure: Adverse events Time: 2 weeks